生物活性：
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11).

体内活性：
Nab-Paclitaxel (30-50 mg/kg，静脉注射，第1、8、15天给药) 显著抑制了横纹肌肉瘤 (RH4 和 RD) 异种移植瘤小鼠的 RH4 肿瘤生长，第 8 天第二次给药后肿瘤消退。 Nab-Paclitaxel (2-10 mg/kg，静脉注射，每日一次) 在 5 和 10 mg/kg 剂量下显著抑制了神经母细胞瘤(SK-N-BE (2) 和 CHLA-20) 异种移植瘤 (皮下) 小鼠的肿瘤生长。 Nab-Paclitaxel (50 mg/kg，静脉注射，每周一次) 具有最强的抗肿瘤活性，并显著延长动物生存期。 Nab-Paclitaxel (10 mg/kg，静脉注射，连续 5 天或 50 mg/kg，静脉注射，每周) 在横纹肌肉瘤和神经母细胞瘤小鼠模型中均显示较低的血浆 Nab-Paclitaxel 浓度，但较高的肿瘤内 Nab-Paclitaxel 浓度。

体外活性：
Nab-Paclitaxel (0.1 nM-10 μM，72 小时) 在 3 种横纹肌肉瘤细胞系、7 种神经母细胞瘤细胞系和 1 种骨肉瘤细胞系中更容易被肿瘤细胞摄取。 Nab-Paclitaxel (12-120 nM，48 小时) 可增加 RH4 细胞凋亡，且在较高浓度 (60 或 120 nM) 下，大多数细胞从盖玻片上脱落。